Alnylam Reports Increased Q4, 2005
Losses Amid Higher R&D Spending
Alnylam Pharmaceuticals this week reported its financial results for the fourth quarter and full-year 2005, posting widening losses amid increased research and development spending.
For the fourth quarter, Alnylam's net loss rose to $14.5 million, or $0.56 per share, from $5.7 million, or $0.29 per share, in the year-ago quarter. For 2005, the company's net loss jumped to $42.9 million, or $1.96 per share, from $35.4 million, or $2.98 per share, the year before.